Vectus Biosystems

Vectus Biosystems Liabilities

The The Liabilities of Vectus Biosystems (VBS.AX) as of Oct 23, 2026 is 1.50 M AUD. In the previous year, The Liabilities was 1.04 M AUD — a change of 44.25% (higher).

Liabilities

1.50 MAUD

YoY

44.25%

Last updated:

In 2026, Vectus Biosystems's total liabilities amounted to 1.50 M AUD, a 44.25% difference from the 1.04 M AUD total liabilities in the previous year.

The Vectus Biosystems Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2019
3.92 M AUD
Jan 1, 2020
9.71 M AUD
Jan 1, 2021
9.88 M AUD
Jan 1, 2022
8.36 M AUD
Jan 1, 2023
1.11 M AUD
Jan 1, 2024
539,262.00 AUD
Jan 1, 2025
1.04 M AUD
Jan 1, 2026
1.50 M AUD
The Vectus Biosystems Liabilities history
YEARLiabilitiesYoY
1.50 MAUD+44.25%
1.04 MAUD+92.72%
539,262.00AUD-51.26%
1.11 MAUD-86.76%
8.36 MAUD-15.39%
9.88 MAUD+1.75%
9.71 MAUD+147.42%
3.92 MAUD+59.99%
2.45 MAUD+306.08%
603,987.00AUD-35.45%
935,750.00AUD+83.27%
510,572.00AUD-22.93%
662,450.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Vectus Biosystems Stock analysis

What does Vectus Biosystems do? Vectus Biosystems Ltd. generates revenue through the development and commercialization of pharmaceutical products targeting fibrotic diseases and hypertension. The company focuses on VB0004, a compound designed to treat tissue hardening and high blood pressure, alongside candidates for fibrotic liver conditions like NASH and pulmonary fibrosis. Its subsidiary Accugen Pty Limited offers the Accugen platform, which provides qPCR reagents and software for accurate DNA and RNA quantification in laboratory testing. The primary buyers of these products are pharmaceutical companies and research institutions seeking advanced drug development tools and therapies for fibrotic disorders. Vectus Biosystems targets the medical research and development sector, specifically addressing unmet needs in fibrotic disease treatment. The Accugen platform serves laboratories requiring efficient molecular analysis tools, with its technology enhancing the speed and precision of qPCR testing. The company’s revenue streams are derived from both therapeutic product development and the sale of diagnostic solutions to biotech firms and academic research entities. The firm’s focus on fibrosis-related treatments, including heart, kidney, and liver diseases, positions it within niche therapeutic segments. Accugen’s reagents and software are sold to laboratories as part of the qPCR workflow, supporting drug discovery processes. Pharmaceutical companies and research organizations are the key segments purchasing Vectus Biosystems’ products for their R&D pipelines and clinical applications. Vectus Biosystems is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Vectus Biosystems's Liabilities

Vectus Biosystems's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Vectus Biosystems's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Vectus Biosystems's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Vectus Biosystems's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Vectus Biosystems’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Vectus Biosystems stock

The Liabilities of Vectus Biosystems is 1.50 M AUD in 2026.

The Liabilities of Vectus Biosystems changed from 1.04 M AUD to 1.50 M AUD, representing a 44.25% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Vectus Biosystems since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Vectus Biosystems historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Vectus Biosystems

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Vectus Biosystems